Francisco Silva - Nov 16, 2021 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Stock symbol
BRTX
Transactions as of
Nov 16, 2021
Transactions value $
$52,632
Form type
4
Date filed
11/16/2021, 04:23 PM
Previous filing
Nov 8, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $26.1K +3.83K +127533.33% $6.83 3.83K Nov 16, 2021 IRA F2
transaction BRTX Common Stock Purchase $26.5K +4K +104.47% $6.63 7.83K Nov 16, 2021 IRA
holding BRTX Common Stock 149K Nov 16, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct F3, F4
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 3 Nov 16, 2021 Common Stock 3 $3,000.00 Direct F3
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 1 Nov 16, 2021 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 9 Nov 16, 2021 Common Stock 9 $3,000.00 Direct F3
holding BRTX Stock Option 6 Nov 16, 2021 Common Stock 6 $3,000.00 Direct F3
holding BRTX Stock Option 15 Nov 16, 2021 Common Stock 15 $3,000.00 Direct F3
holding BRTX Stock Option 20 Nov 16, 2021 Common Stock 20 $3,000.00 Direct F3
holding BRTX Stock Option 25 Nov 16, 2021 Common Stock 25 $3,000.00 Direct F3
holding BRTX Stock Option 293K Nov 16, 2021 Common Stock 293K $13.50 Direct F5
holding BRTX Stock Option 42.1K Nov 16, 2021 Common Stock 42.1K $13.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.73 to $6.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
F3 The option is currently exercisable.
F4 The option is exercisable subject to the satisfaction of certain conditions.
F5 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F6 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.